Mannkind (MNKD) Amortization of Deferred Charges (2015 - 2026)
Mannkind (MNKD) reported Amortization of Deferred Charges of $452000.0 for Q1 2026, up 314.68% year-over-year from $109000.0 in Q1 2025, and up 67.41% quarter-over-quarter from $270000.0 in Q4 2025.
Mannkind (MNKD) Amortization of Deferred Charges (2015 - 2026) Analysis & Trends
Mannkind (MNKD) has 9 years of Amortization of Deferred Charges data on file, last reported at $452000.0 in Q1 2026.
- Amortization of Deferred Charges for Q1 2026 came in at $452000.0, up 314.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $885000.0 (down 22.91% YoY), and the FY2025 annual result was $646000.0, down 60.75% from the prior year.
- Amortization of Deferred Charges rose to $452000.0 in Q1 2026 per MNKD's latest filing, from $270000.0 in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $469000.0 in Q1 2022 and troughed at -$114000.0 in Q4 2022.
- A 5-year average of $296235.3 and a median of $363000.0 in 2022 frame the typical range for Amortization of Deferred Charges.
- The sharpest annual moves came in 2023 and 2025: Amortization of Deferred Charges soared 419.3% in 2023, then plunged 84.3% in 2025.
- A 5-year view of Amortization of Deferred Charges shows it stood at -$114000.0 in 2022, then soared by 419.3% to $364000.0 in 2023, then retreated by 14.01% to $313000.0 in 2024, then slipped by 13.74% to $270000.0 in 2025, then soared by 67.41% to $452000.0 in 2026.
- Business Quant data shows MNKD's Amortization of Deferred Charges at $452000.0 in Q1 2026, $270000.0 in Q4 2025, and $106000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Mannkind | 1.21 Bn | 1.08 Bn | 82.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 452,000.00 |
| Mar 31, 2026 | 452,000.00 |
| Dec 31, 2025 | 270,000.00 |
| Dec 31, 2025 | 270,000.00 |
| Sep 30, 2025 | 106,000.00 |
| Sep 30, 2025 | 106,000.00 |
| Jun 30, 2025 | 57,000.00 |
| Jun 30, 2025 | 57,000.00 |
| Mar 31, 2025 | 109,000.00 |
| Mar 31, 2025 | 109,000.00 |
| Dec 31, 2024 | 313,000.00 |
| Dec 31, 2024 | 313,000.00 |
| Sep 30, 2024 | 363,000.00 |
| Sep 30, 2024 | 363,000.00 |
| Jun 30, 2024 | 363,000.00 |
| Jun 30, 2024 | 363,000.00 |
| Mar 31, 2024 | 363,000.00 |
| Mar 31, 2024 | 363,000.00 |
| Dec 31, 2023 | 364,000.00 |
| Dec 31, 2023 | 364,000.00 |